Infinium Pharmachem Ltd Stock Price Today (NSE: INFINIUM)
Fundamental Score
Infinium Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Infinium Pharmachem Ltd share price today is ₹192.80, down 0.37% on NSE/BSE as of 30 March 2026. Infinium Pharmachem Ltd (INFINIUM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹371.03 (Cr). The 52-week high for INFINIUM share price is ₹337.00 and the 52-week low is ₹198.00. At a P/E ratio of 39.73x, INFINIUM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.95% and a debt-to-equity ratio of 0.00.
Infinium Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Infinium Pharmachem Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Infinium Pharmachem Share Price: A Financial Stability Analysis
The pharmaceutical industry, inherently resilient due to constant healthcare needs, still demands stringent financial scrutiny. This analysis focuses on the financial stability of Infinium Pharmachem Ltd, with a particular lens on the "Infinium Pharmachem share price," currently trading at ₹220.0. A key indicator of value, the Price-to-Earnings (PE) ratio, sits at 39.73, suggesting a market expectation of future earnings growth, which must be critically assessed against the company's operational efficiency and competitive landscape.
Return on Capital Employed (ROCE), a crucial metric for evaluating profitability and capital allocation, stands at 14.58% for Infinium Pharmachem. This indicates the company's efficiency in generating profits from its capital. A higher ROCE typically signifies a wider economic moat. In Infinium Pharmachem's case, a ROCE of 14.58% contributes towards, but doesn't definitively guarantee, a significant competitive advantage within the specialty chemicals and pharmaceutical raw materials sector. Sustained or improving ROCE figures are crucial for long-term value creation.
When evaluating Infinium Pharmachem, a comparison with its peers is essential. For instance, a look at
Mankind Pharma Ltd reveals differences in management quality, often reflected in various operational efficiencies and strategic decisions. While difficult to quantify precisely, strong management often translates to better capital allocation and faster responses to market changes, ultimately impacting shareholder value. Further comparison of management track records and strategic visions would provide added perspective.This observational analysis of Infinium Pharmachem's financial stability, including the "Infinium Pharmachem share price," is part of a comprehensive 80-parameter fundamental audit, independently verified by Sweta Mishra. It is intended for informational purposes and should not be construed as investment advice. The analysis considers factors such as the PE ratio, ROCE, and relative position within the pharmaceutical sector, but doesn't constitute a recommendation to buy or sell the company's shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Infinium Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INFINIUM across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (26.98%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (32.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (60.97% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (59.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-25.96 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Infinium Pharmachem Ltd Financial Statements
Comprehensive financial data for Infinium Pharmachem Ltd including income statement, balance sheet and cash flow
About INFINIUM (Infinium Pharmachem Ltd)
Infinium Pharmachem Ltd (INFINIUM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with ...a current market capitalisation of ₹371.03 (Cr). Infinium Pharmachem Ltd has delivered a Return on Equity (ROE) of 11.95% and a ROCE of 14.58%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking INFINIUM share price can monitor key metrics including P/E ratio, promoter holding of 59.91%, and quarterly earnings growth.
Company Details
INFINIUM Share Price: Frequently Asked Questions
What is the current share price of Infinium Pharmachem Ltd (INFINIUM)?
As of 30 Mar 2026, 12:03 pm IST, Infinium Pharmachem Ltd share price is ₹192.80. The INFINIUM stock has a market capitalisation of ₹371.03 (Cr) on NSE/BSE.
Is INFINIUM share price Overvalued or Undervalued?
INFINIUM share price is currently trading at a P/E ratio of 39.73x, compared to the industry average of 31.77x. Based on this relative valuation, the Infinium Pharmachem Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of INFINIUM share price?
The 52-week high of INFINIUM share price is ₹337.00 and the 52-week low is ₹198.00. These values are updated daily from NSE/BSE price data.
What factors affect the Infinium Pharmachem Ltd share price?
Key factors influencing INFINIUM share price include quarterly earnings growth (Sales Growth: 1.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Infinium Pharmachem Ltd a good stock for long-term investment?
Infinium Pharmachem Ltd shows a 5-year Profit Growth of 60.97% and an ROE of 11.95%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in INFINIUM shares.
How does Infinium Pharmachem Ltd compare with its industry peers?
Infinium Pharmachem Ltd competes with major peers in the Pharmaceuticals. Investors should compare INFINIUM share price P/E of 39.73x and ROE of 11.95% against the industry averages to determine competitive standing.
What is the P/E ratio of INFINIUM and what does it mean?
INFINIUM share price has a P/E ratio of 39.73x compared to the industry average of 31.77x. Investors pay ₹40 for every ₹1 of annual earnings.
How is INFINIUM performing according to Bull Run's analysis?
INFINIUM has a Bull Run fundamental score of 50.6/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INFINIUM belong to?
INFINIUM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Infinium Pharmachem Ltd share price.
What is Return on Equity (ROE) and why is it important for INFINIUM?
INFINIUM has an ROE of 11.95%, which shows decent profitability but room for improvement. ROE measures how efficiently Infinium Pharmachem Ltd generates profits from shareholders capital.
How is INFINIUM debt-to-equity ratio and what does it indicate?
INFINIUM has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is INFINIUM dividend yield and is it a good dividend stock?
INFINIUM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Infinium Pharmachem Ltd shares.
How has INFINIUM share price grown over the past 5 years?
INFINIUM has achieved 5-year growth rates of: Sales Growth 32.01%, Profit Growth 60.97%, and EPS Growth 6.76%.
What is the promoter holding in INFINIUM and why does it matter?
Promoters hold 59.91% of INFINIUM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Infinium Pharmachem Ltd.
What is INFINIUM market capitalisation category?
INFINIUM has a market capitalisation of ₹371 crores, placing it in the Small-cap category.
How volatile is INFINIUM stock?
INFINIUM has a beta of N/A. A beta > 1 suggests the Infinium Pharmachem Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INFINIUM operating profit margin trend?
INFINIUM has a 5-year average Operating Profit Margin (OPM) of 11.96%, indicating the company's operational efficiency.
How is INFINIUM quarterly performance?
Recent quarterly performance shows Infinium Pharmachem Ltd YoY Sales Growth of 1.29% and YoY Profit Growth of 26.98%.
What is the institutional holding pattern in INFINIUM?
INFINIUM has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the Infinium Pharmachem Ltd stock.